NDAORALTABLET, CHEWABLE
Approved
Dec 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SORBITRATE (isosorbide dinitrate) by AstraZeneca is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. First approved in 1970.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SORBITRATE is an oral chewable tablet formulation of isosorbide dinitrate, an organic nitrate indicated for heart failure. It works by relaxing vascular smooth muscle to dilate peripheral arteries and veins, reducing preload and afterload on the heart while promoting coronary artery dilatation.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job activity, SORBITRATE represents a declining commercial opportunity with likely reductions in brand team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on SORBITRATE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.